Agios Pharmaceuticals (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Read More
Trailing Twelve Months EPS: $11.36
2024 EPS Estimate: ($0.26)
2025 EPS Estimate: ($6.36)
- Current Stock Price
- $55.01
- P/E Ratio
- 4.8
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 4 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $52.33 (4.9% Downside)
